Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome-Reference-Cited by-同舟云学术

Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome

Published:2020-08-28 Issue:2 Volume:29 Page:127-135
ISSN:1541-2016
Container-title:Applied Immunohistochemistry & Molecular Morphology
language:en
Short-container-title:

Author:

Lombardo Kara A.,Murati Amador Belkiss,Parimi Vamsi,Hoffman-Censits Jean,Choi Woonyoung,Hahn Noah M.,Kates Max,Bivalacqua Trinity J.,McConkey David,Hoque Mohammad O.,Matoso Andres

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Medical Laboratory Technology,Histology,Pathology and Forensic Medicine

Reference28 articles.

1. Survival of patients with carcinoma in situ of the urinary bladder;Cheng;Cancer,1999

2. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and alpha-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia;Aron;Am J Surg Pathol,2013

3. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference;Amin;Am J Surg Pathol,2014

4. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia;Mallofre;Mod Pathol,2003

5. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder;Sun;Appl Immunohistochem Mol Morphol,2002

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer;Proceedings of the National Academy of Sciences;2024-09-05

2. Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ;Medicina;2023-09-06

3. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder;Experimental and Molecular Pathology;2023-06

4. Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling;Cancer Research;2021-01-20